China National Medical Products Administration (NMPA) has granted acceptance and priority review for the new drug application ...

The firm also announced that it was divesting most of its equity interest in Shanghai Hutchison Pharmaceuticals to invest in its own pipeline.

In a move designed to advance its pipeline and its “innovative medicines business,” Chinese biotech Hutchmed will ...

Hutchmed China announced a number of advancements on Thursday, including a regulatory milestone for its lung cancer treatment ...

The JV was set up in 2001 and has become increasingly peripheral to Hutchmed's core business of developing novel therapies ...

Hutchmed sells a 45% stake in SHPL for $608 million and focuses on advancing its cancer and immunology pipeline, including ...

Hutchmed also on Thursday said a new drug application has been accepted with priority review status in China for the combination of drugs Orpathys and Tagrisso. The two treatments are used in the care ...

Limited, a biopharmaceutical company under Hong Kong-listed conglomerate CK Hutchison Holdings, has agreed to sell its 45% ...

Limited (HK:0013) has released an update.Don't Miss Our New Year's Offers:Discover the latest stocks recommended by top Wall ...

Hutchmed (HCM) announces that the new drug application for the combination of Orpathys and Tagrisso for the treatment of patients with locally ...

Hutchmed (China), controlled by tycoon Li Ka-shing, is selling stakes in its health subsidiary for around $608 million as the billionaire and his flagship conglomerate look to ramp up capital and ...

HUTCHMED (China) Limited, together with its subsidiaries, discovers, develops, and commercializes targeted therapeutics and immunotherapies for cancer and immunological diseases in Hong Kong and ...